Citations

Showing 10 of 108104 citations.

Manifestations of Alzheimer’s Disease Genetic Risk in the Blood: A Cross-Sectional Multi-Omic Analysis in Healthy Adults Aged 18-90+
Earls, John C. , Lovejoy, Jennifer C., Funk, Cory C. , Rappaport, Noa , Kunkle, Brian W. , Martin, Eden R. , Ertekin‐Taner, Nilüfer , Golde, Todd E. , Rappaport, Noa , Heath, Laura , Magis, Andrew T. , Kornilov, Sergey A. , Logsdon, Ben , Mangravite, Lara M. , Naj, Adam Christian , Hood, Leroy , Price, Nathan D.

Mayo Clinic

No container title available | January 20, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1108842/v2 Get It

Abstract Background Genetics play an important role in late-onset Alzheimer’s Disease (AD) etiology and dozens of genetic variants have been implicated in AD risk through large-scale GWAS meta-analyses. However, the precise mechanistic effects of most of these variants have yet to be determined. Deeply phenotyped cohort data can reveal physiological changes associated with genetic risk for AD across an age spectrum that may provide clues to the biology of the disease. Methods We utilized over 2000 high-quality quantitative measurements obtained from blood of 2831 cognitively normal adult clients of a consumer-based scientific wellness company, each with CLIA-certified whole-genome sequencing data. Measurements included: clinical laboratory blood tests, targeted chip-based proteomics, and metabolomics. We performed a phenome-wide association study utilizing this diverse blood marker data and 25 known AD genetic variants, adjusting for sex, age, vendor (for clinical labs), and the first four genetic principal components; sex-SNP interactions were also assessed. Results We observed statistically significant SNP-analyte associations for five genetic variants after correction for multiple testing (for SNPs in or near NYAP1, ABCA7, INPP5D, and APOE), with effects detectable from early adulthood. The ABCA7 SNP and the APOE2 and APOE4 encoding alleles were associated with lipid variability, as seen in previous studies; in addition, six novel proteins were associated with the e2 allele. The most statistically significant finding was between the NYAP1 variant and PILRA and PILRB protein levels, supporting previous functional genomic studies in the identification of a putative causal variant within the PILRA gene. Sex modified the effects of four genetic variants, with multiple interrelated immune-modulating effects associated with the PICALM variant. In post-hoc analysis, sex-stratified GWAS results from an independent AD case-control meta-analysis supported sex-specific disease effects of the PICALM variant, highlighting the importance of sex as a biological variable. Conclusions Known AD genetic variation influenced lipid metabolism and immune response systems in a population of non-AD individuals, with associations observed from early adulthood onward. Further research is needed to determine whether and how these effects are implicated in early-stage biological pathways to AD. These analyses aim to complement ongoing work on the functional interpretation of AD-associated genetic variants.
Identifying the underlying factors associated with antidepressant drug discontinuation: content analysis of patients’ drug reviews
Alarifi, Mohammad , Jabour, Abdulrahman , Foy, Doreen M, Zolnoori, Maryam , Foy, Doreen

Mayo Clinic

Informatics for Health and Social Care | January 20, 2022 | Volume: 47 | Issue: 4 | Pages: 414-423

10.1080/17538157.2021.2024835 | PMID 35050827 Get It

Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy
Jing, Ying , Chen, Xue , Chen, Xue, Li, Kunyan , Liu, Yaoming , Liu, Yuan , Lin, Steven H. , Diao, Lixia , Lou, Yanyan , Johnson, Douglas B. , Han, Leng , Lin, Steven H , Han, Leng , Chen, Xue, Zhang, Zhao , Chen, Yiqing , Wang, Yushu , Wang, Jing , Chen, Xiang , Liu, Hong

Mayo Clinic

Journal for ImmunoTherapy of Cancer | January 20, 2022 | Volume: 10 | Issue: 1 | Pages: e003779

10.1136/jitc-2021-003779 | PMID 35058327 Get It

Background To determine whether antibiotic treatment is a risk factor for immune-related adverse events (irAEs) across different patients with cancer receiving anti-PD-1/PD-L1 therapies. Methods The retrospective analysis includes clinical information from 767 patients with cancer treated at Hunan Cancer Hospital from 2017 to 2020. The pharmacovigilance data analysis includes individual cases of 38,705 safety reports from the US Food and Drug Administration Adverse Event Reporting System (FAERS) from 2014 to 2020, and 25,122 cases of safety reports from the World Health Organization database VigiBase from 2014 to 2019. All cases that received anti-PD-1/PD-L1 treatment were included. Multiomics data from patients across 25 cancer types were download from The Cancer Genome Atlas. Logistic regression and propensity score algorithm was employed to calculate OR of irAEs. Results Retrospective analysis of in-house patients showed that irAE potential risks are higher in all cancer (OR 2.12, 95% CI 1.38 to 3.22, false discovery rate (FDR) adjusted-p=1.93×10−3) and patients with lung cancer (OR 3.16, 95% CI 1.67 to 5.95, FDR adjusted-p=1.93×10−3) when using antibiotics. Potential risk of irAEs in patients with lung cancer with antibiotic treatment is significantly higher in FAERS (OR 1.39, 95% CI 1.21 to 1.59; FDR adjusted-p=1.62×10−5) and VigiBase (OR 1.32, 95% CI 1.09 to 1.59, FDR adjusted-p=0.05). Mechanistically, decreased microbial diversity caused by antibiotics use may increase the irAE risk through mediating the irAE-related factors. Conclusions Our study is the first to comprehensively demonstrate the associations of irAEs and antibiotic during anti-PD-1/PD-L1 therapy across a wide spectrum of cancers by analyzing multisource data. Administration of antibiotics should be carefully evaluated in patients with cancer treated by anti-PD-1/PD-L1 to avoid potentially increasing irAE risk.
MANP (M-Atrial Natriuretic Peptide) Reduces Blood Pressure and Furosemide-Induced Increase in Aldosterone in Hypertension
Dzhoyashvili, Nina , Iyer, Seethalakshmi R., Chen, Horng H. , Burnett, John C., Dzhoyashvili, Nina A , Iyer, Seethalakshmi R., Chen, Horng , Burnett, John C.

Mayo Clinic

Hypertension | January 20, 2022 | Volume: 79 | Issue: 4 | Pages: 750-760

10.1161/hypertensionaha.121.18837 | PMID 35045724 Get It

Background: cGMP MANP (M-atrial natriuretic peptide) is a best-in-class activator of the pGC-A (particulate guanylyl cyclase A) receptor. Furosemide increases the effectiveness of antihypertensive agents, but activates renin-angiotensin-aldosterone system. We aimed to investigate for the first time cardiorenal and neurohumoral actions of MANP in a genetic model of hypertension in spontaneously hypertensive rats. We also assessed how MANP would potentiate the blood pressure (BP)–lowering actions of furosemide while reducing the production of aldosterone. Methods: Spontaneously hypertensive rats (N=60) were randomized in vehicle, MANP, furosemide, or MANP+furosemide groups. Furosemide (1, 5, 10 mg/kg) was given as a single bolus which in MANP+furosemide groups was followed by a 60-minute infusion of MANP. Results: BP was reduced in MANP300 (300 pmol/[kg·min]) and MANP600 (600 pmol/[kg·min]) groups ( P <0.05) and was accompanied by significant increase in plasma cyclic guanosine monophosphate. Furosemide alone reduced BP but less compared with MANP with no change in plasma cyclic guanosine monophosphate. MANP+furosemide resulted in the greatest BP reduction and significant increase in plasma cyclic guanosine monophosphate in Fs5+MANP300, Fs10+MANP300, and Fs10+MANP600. Plasma aldosterone increased in furosemide groups, which was significantly attenuated in MANP+furosemide groups. Natriuresis and diuresis increased in all treated groups ( P <0.05) with no significant differences between furosemide and furosemide+MANP. In vitro, MANP increased cyclic guanosine monophosphate level in human vascular cells. Conclusions: We provide novel evidence that MANP potentiates the BP-lowering actions of furosemide, suppresses the activation of renin-angiotensin-aldosterone system, and preserves renal function. These data are highly relevant to clinical needs in the treatment of hypertension and heart failure.
DPP4 (Dipeptidyl Peptidase-4) Inhibition Increases Catecholamines Without Increasing Blood Pressure During Sustained ACE (Angiotensin-Converting Enzyme) Inhibitor Treatment
Wilson, Jessica R. , Garner, Erica M. , Mashayekhi, Mona , Hubers, Scott , Bustamante, Claudia E. Ramirez , Nian, Hui, Shibao, Cyndya A. , Brown, Nancy J. , Hubers, Scott A , Ramirez Bustamante, Claudia E , Kerman, Scott Jafarian , Shibao, Cyndya A , Brown, Nancy J , Wilson, Jessica R. , Garner, Erica M. , Mashayekhi, Mona , Nian, Hui

Mayo Clinic

Hypertension | January 20, 2022 | Volume: 79 | Issue: 4 | Pages: 827-835

10.1161/hypertensionaha.121.18348 | PMID 35045722 Get It

Background: DPP4 (dipeptidyl peptidase-4) inhibitors comprise a class of oral diabetes medication that have the potential for off-target cardiovascular effects. We previously showed that DPP4 inhibition attenuates the hypotensive effect of acute ACE (angiotensin-converting enzyme) inhibition and increases norepinephrine. Here, we investigated the effects of DPP4 during sustained ACE inhibition compared with during therapy with an ARB (angiotensin receptor blocker) or calcium channel blocker (neutral comparator) in a randomized, double-blinded crossover study. Methods: We enrolled 106 adults with type 2 diabetes and hypertension and 100 received intervention. Subjects were randomized to one of 3 blood pressure arms: ramipril, valsartan, or amlodipine for a total of 15 weeks and received 3 one-week crossover therapies in random order: placebo + placebo, sitagliptin + placebo, and sitagliptin + aprepitant separated by 4-week washout. Results: We found that DPP4 inhibition increased norepinephrine during ramipril but did not increase blood pressure. Aprepitant, a NK1 (substance P) receptor blocker, lowered standing heart rate during renin-angiotensin-aldosterone system blockade with ramipril or valsartan. Conclusions: Increased catecholamines during concurrent ACE and DPP4 inhibition may contribute to cardiovascular complications in patients predisposed to heart failure.
Outpatient Randomized Crossover Automated Insulin Delivery Versus Conventional Therapy with Induced Stress Challenges
Kaur, Ravinder Jeet , Pinsker, Jordan E. , Gilliam, Wesley P. , McCrady-Spitzer, Shelly , Desjardins, Donna, Church, Mei Mei , Kremers, Walter K. , Dassau, Eyal , Kudva, Yogish C. , Pinsker, Jordan E , Zaniletti, Isabella, Dassau, Eyal , Kudva, Yogish C. , Kremers, Walter K , Deshpande, Sunil , Zaniletti, Isabella , Doyle, Francis J.

Mayo Clinic

Diabetes Technology & Therapeutics | January 20, 2022 | Volume: 24 | Issue: 5 | Pages: 338-349

10.1089/dia.2021.0436 | PMID 35049354 Get It

Background: Automated insulin delivery (AID) systems have not been evaluated in the context of psychological and pharmacological stress in type 1 diabetes. Our objective was to determine glycemic control and insulin use with Zone Model Predictive Control (zone-MPC) AID system enhanced for states of persistent hyperglycemia versus sensor-augmented pump (SAP) during outpatient use, including in-clinic induced stress. Materials and Methods: Randomized, crossover, 2-week trial of zone-MPC AID versus SAP in 14 adults with type 1 diabetes. In each arm, each participant was studied in-clinic with psychological stress induction (Trier Social Stress Test [TSST] and Socially Evaluated Cold Pressor Test [SECPT]), followed by pharmacological stress induction with oral hydrocortisone (total four sessions per participant). The main outcomes were 2-week continuous glucose monitor percent time in range (TIR) 70–180 mg/dL, and glucose and insulin outcomes during and overnight following stress induction. Results: During psychological stress, AID decreased glycemic variability percentage by 13.4% ( P = 0.009). During pharmacological stress, including the following overnight, there were no differences in glucose outcomes and total insulin between AID and physician-assisted SAP. However, with AID total user-requested insulin was lower by 6.9 U ( P = 0.01) for pharmacological stress. Stress induction was validated by changes in heart rate and salivary cortisol levels. During the 2-week AID use, TIR was 74.4% (vs. SAP 63.1%, P = 0.001) and overnight TIR was 78.3% (vs. SAP 63.1%, P = 0.004). There were no adverse events. Conclusions: Zone-MPC AID can reduce glycemic variability and the need for user-requested insulin during pharmacological stress and can improve overall glycemic outcomes. Clinical Trial Identifier NCT04142229.
HIV Infection Is an Independent Predictor of Mortality Among Adults with Reduced Level of Consciousness in Uganda
Mbonde, Amir A. , Mbatidde, Lydia, Aden, Abdirahim Abdi, Butterfield, Richard , Muhindo, Rose , Kayanja, Adrian, O’Carroll, Cumara B. , O'Carroll, Cumara B., Demaerschalk, Bart M. , Zhang, Nan

Mayo Clinic

The American Journal of Tropical Medicine and Hygiene | January 20, 2022 | Volume: 106 | Issue: 3 | Pages: 909-914

10.4269/ajtmh.21-0813 | PMID 35026731 Get It

ABSTRACT. The clinical epidemiology of adults admitted with reduced level of consciousness (LOC) in sub-Saharan Africa (SSA) and the impact of HIV infection on the risk of mortality in this population is unknown. We secondarily analyzed data from a cohort study that enrolled 359 consecutive adults with reduced LOC presenting to Mbarara Regional Hospital in Uganda with the aim of comparing the prognostic utility of the Full Outline of Unresponsiveness (FOUR) score to the Glasgow Coma Scale (GCS) Score. For this analysis, we included 336 individuals with known HIV serostatus, obtaining clinical, laboratory, and follow-up data. We recorded investigations and treatments deemed critical by clinicians for patient care but were unavailable. We computed mortality rates and used logistic regression to determine predictors of 30-day mortality. The median GCS was 10. Persons living with HIV infection (PLWH) accounted for 97 of 336 (29%) of the cohort. The 30-day mortality rate in the total cohort was 148 of 329 (45%), and this was significantly higher in PLWH (57% versus 40%, adjusted odds ratio [aOR] 2.39: 95% confidence interval [CI]: 1.31–4.35, P = 0.0046). Other predictors of mortality were presence of any unmet clinical need (aOR 1.72; 95% CIL 1.04–2.84, P = 0.0346), anemia (aOR 1.68; 95% CI: 1.01–2.81, P = 0.047), and admission FOUR score < 12 [aOR 4.26; 95% CI: 2.36–7.7, P < 0.0001). Presentation with reduced LOC in Uganda is associated with high mortality rates, with worse outcomes in PLWH. Improvement of existing acute care services is likely to improve outcomes.
Cellular senescence: all roads lead to mitochondria
Martini, Hélène , Passos, João F. , Passos, João F

Mayo Clinic

The FEBS Journal | January 20, 2022 | Volume: 290 | Issue: 5 | Pages: 1186-1202

10.1111/febs.16361 | PMID 35048548 Get It

Senescence is a multi‐functional cell fate, characterized by an irreversible cell‐cycle arrest and a pro‐inflammatory phenotype, commonly known as the senescence‐associated secretory phenotype (SASP). Emerging evidence indicates that accumulation of senescent cells in multiple tissues drives tissue dysfunction and several age‐related conditions. This has spurred the academic community and industry to identify new therapeutic interventions targeting this process. Mitochondrial dysfunction is an often‐unappreciated hallmark of cellular senescence which plays important roles not only in the senescence growth arrest but also in the development of the SASP and resistance to cell‐death. Here, we review the evidence that supports a role for mitochondria in the development of senescence and describe the underlying mechanisms. Finally, we propose that a detailed road map of mitochondrial biology in senescence will be crucial to guide the future development of senotherapies.
Editor's evaluation: ZAF, the first open source fully automated feeder for aquatic facilities
Ekker, Stephen C.

Mayo Clinic

No container title available | January 20, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.74234.sa0 Get It

Endoscopic Treatment of GERD in Patients With Obesity
Ghazi, Rabih , Rapaka, Babusai , Dayyeh, Barham K. Abu

Mayo Clinic

Foregut: The Journal of the American Foregut Society | January 20, 2022 | Volume: 1 | Issue: 4 | Pages: 336-349

10.1177/26345161211069890 Get It

Gastroesophageal reflux disease (GERD) is one of the most common obesity-associated comorbidities. The increasing prevalence of obesity worldwide is expected to cause a concomitant increase in the prevalence of GERD. While laparoscopic Nissen fundoplication (LNF) remains the gold standard for the treatment of GERD, its efficacy in the setting of obesity is limited by a relatively high rate of post-procedural reflux recurrence. Currently, Roux-en-Y gastric bypass (RYGB) is the gold standard treatment for GERD in patients with obesity. However, despite its proven efficacy, it remains underutilized due to its cost, safety concerns, and patient acceptance. During the past 2 decades, endoscopic therapies have emerged as minimally invasive and safe alternatives for the management of GERD. While most studies assessed their outcomes in patients without obesity, recently published case reports offered a potential framework for their use in patients with obesity. In this article, we review the available endoscopic anti-reflux therapies (EART) and endoscopic bariatric therapies (EBT), with emphasis on their potential role in the management of GERD in patients with obesity.